156 related articles for article (PubMed ID: 14978517)
1. Therapeutic potentials of sarpogrelate in cardiovascular disease.
Saini HK; Takeda N; Goyal RK; Kumamoto H; Arneja AS; Dhalla NS
Cardiovasc Drug Rev; 2004; 22(1):27-54. PubMed ID: 14978517
[TBL] [Abstract][Full Text] [Related]
2. Sarpogrelate: cardiovascular and renal clinical potential.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jul; 13(7):865-74. PubMed ID: 15212624
[TBL] [Abstract][Full Text] [Related]
3. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
4. Sarpogrelate treatment reduces restenosis after coronary stenting.
Fujita M; Mizuno K; Ho M; Tsukahara R; Miyamoto A; Miki O; Ishii K; Miwa K
Am Heart J; 2003 Mar; 145(3):E16. PubMed ID: 12660685
[TBL] [Abstract][Full Text] [Related]
5. Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Chen YX; Wang WD; Song XJ; Gu YQ; Tian HY; Hu HJ; Zhao JC; Li XQ; Liu CW
Chin Med J (Engl); 2015 Jun; 128(12):1563-6. PubMed ID: 26063354
[TBL] [Abstract][Full Text] [Related]
6. Effect of sarpogrelate, a selective 5-HT
Lee DH; Chun EJ; Hur JH; Min SH; Lee JE; Oh TJ; Kim KM; Jang HC; Han SJ; Kang DK; Kim HJ; Lim S
Atherosclerosis; 2017 Feb; 257():47-54. PubMed ID: 28068560
[TBL] [Abstract][Full Text] [Related]
7. Exploring the antiplatelet activity of serotonin 5-HT
Marcinkowska M; Kubacka M; Zagorska A; Jaromin A; Fajkis-Zajaczkowska N; Kolaczkowski M
Biomed Pharmacother; 2022 Jan; 145():112424. PubMed ID: 34785417
[TBL] [Abstract][Full Text] [Related]
8. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
Hironaka E; Hongo M; Sakai A; Mawatari E; Terasawa F; Okumura N; Yamazaki A; Ushiyama Y; Yazaki Y; Kinoshita O
Cardiovasc Res; 2003 Dec; 60(3):692-9. PubMed ID: 14659815
[TBL] [Abstract][Full Text] [Related]
9. Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts.
Gocht A; Distler JHW; Spriewald B; Ramsperger-Gleixner M; Weyand M; Ensminger SM; Heim C
Transpl Immunol; 2018 Aug; 49():43-53. PubMed ID: 29649585
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts.
Muto T; Hotta Y; Miyazeki K; Ando H; Ishikawa N; Hasegawa T; Sugimoto Y; Yamada J; Miki Y
Mol Cell Biochem; 2005 Apr; 272(1-2):119-32. PubMed ID: 16010979
[TBL] [Abstract][Full Text] [Related]
11. Effect of sarpogrelate hydrochloride, a 5-hydroxytryptamine2 receptor antagonist, on allograft arteriosclerosis after aortic transplantation in rats.
Watada S; Harada H; Matsubara K; Obara H; Matsumoto K; Ando N; Kitagawa Y
Transpl Immunol; 2013 Dec; 29(1-4):162-6. PubMed ID: 23851153
[TBL] [Abstract][Full Text] [Related]
12. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
[TBL] [Abstract][Full Text] [Related]
13. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Kobayashi S; Satoh M; Namikoshi T; Haruna Y; Fujimoto S; Arakawa S; Komai N; Tomita N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2008 Apr; 12(2):119-125. PubMed ID: 18175064
[TBL] [Abstract][Full Text] [Related]
14. Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.
Muntasir HA; Bhuiyan MA; Ishiguro M; Ozaki M; Nagatomo T
J Pharmacol Sci; 2006 Oct; 102(2):189-95. PubMed ID: 17031071
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate.
Saini HK; Sharma SK; Zahradka P; Kumamoto H; Takeda N; Dhalla NS
Can J Physiol Pharmacol; 2003 Nov; 81(11):1056-63. PubMed ID: 14719041
[TBL] [Abstract][Full Text] [Related]
16. Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Yamada K; Niki H; Nagai H; Nishikawa M; Nakagawa H
J Pharmacol Sci; 2012; 119(3):243-50. PubMed ID: 22785018
[TBL] [Abstract][Full Text] [Related]
17. Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT
Kubacka M; Kazek G; Kotańska M; Filipek B; Waszkielewicz AM; Mogilski S
Eur J Pharmacol; 2018 Jan; 818():263-270. PubMed ID: 29111111
[TBL] [Abstract][Full Text] [Related]
18. Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease.
Horibe E; Nishigaki K; Minatoguchi S; Fujiwara H
Circ J; 2004 Jan; 68(1):68-72. PubMed ID: 14695468
[TBL] [Abstract][Full Text] [Related]
19. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.
Umrani DN; Bodiwala DN; Goyal RK
Mol Cell Biochem; 2003 Jul; 249(1-2):53-7. PubMed ID: 12956398
[TBL] [Abstract][Full Text] [Related]
20. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.
Yoshimasu T; Ikeda T; Uede K; Kanazawa N; Furukawa F
J Dermatol; 2012 Jun; 39(6):536-40. PubMed ID: 22077618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
